Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office
Welcome,         Profile    Billing    Logout  
 9 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patel, Manish
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
ANZUP 1301, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Active, not recruiting
3
501
Europe, RoW
Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia
Bladder Cancer
12/24
12/24
BTCRC-HN17-111, NCT03942653: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Recruiting
2
20
US
Goserelin Acetate, Pembrolizumab
Manish Patel, Merck Sharp & Dohme LLC
Salivary Gland Carcinoma
09/25
10/25
NCT04291105: Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
06/25
12/25
VitalBE, NCT03696290 / 2018-001590-24: Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Recruiting
2
77
Europe
Aztreonam lysine, Cayston, Placebo, Lactose monohydrate
University of Dundee, Gilead Sciences
Bronchiectasis Adult
09/25
09/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, ZIIHERA®, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
09/25
09/25
KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Recruiting
1/2
314
US
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Kineta Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
06/24
12/24
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
ARTS-021-1001, NCT05867251: Study of AVZO-021 in Patients With Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
AVZO-021, Palbociclib, Ibrance, Fulvestrant, Faslodex, Letrozole, Femara, Ribociclib, Kisqali, Abemaciclib, Verzenio, Carboplatin, Sacituzumab Govitecan-hziy, Trodelvy
Avenzo Therapeutics, Inc.
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
01/28
01/30
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25
NCT06065059: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Terminated
1/2
7
US
TNG348, Olaparib, Lynparza
Tango Therapeutics, Inc.
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
05/24
05/24
NCT06028074: Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
111
US
GIM122, GIM-122
Georgiamune Inc
Advanced Solid Malignancies
09/26
12/26
REFMAL 412, NCT02617277: Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Active, not recruiting
1
56
US
AZD1775, Adavosertib, MEDI4736, Durvalumab
AstraZeneca
Advanced Solid Tumours
04/19
12/25
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
KEYNOTE-D26, NCT04840394: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Completed
1
1
US
BDB018, Pembrolizumab
Eikon Therapeutics, Merck Sharp & Dohme LLC
Tumor, Solid
03/24
09/24
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
FT825-101, NCT06241456: FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors

Recruiting
1
351
US
FT825, ONO-8250, Fludarabine, FLUDARA, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab
Fate Therapeutics
Advanced Solid Tumor
05/29
05/44
CUSP06-1001, NCT06234423: A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Recruiting
1
180
US
CUSP06
OnCusp Therapeutics, Inc.
Ovarian Cancer, Solid Tumor
05/27
08/27
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
07/25
10/25
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
CLN-418-001, NCT05306444: CLN-418 Study on Subjects With Advanced Solid Tumors

Completed
1
48
US, RoW
CLN-418, HBM7008
Harbour BioMed US, Inc., Harbour BioMed US, Inc.
Advanced Solid Tumor
08/24
09/24
NCT06714617: Phase 1 Open-Label Study BL-M17D1 w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Recruiting
1
120
US
BL-M17D1
SystImmune Inc.
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
09/27
12/27
CPO301-US-101, NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
102
Canada, US
CPO301, SYS6010
Conjupro Biotherapeutics, Inc.
Cancer, Cancer, Lung
06/25
12/25
NCT05462873: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Active, not recruiting
1
30
Europe, Japan, US, RoW
QEQ278
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
09/25
09/25
NCT05377528: Study of AGEN1571 in Participants With Advanced Solid Tumors

Completed
1
22
US
AGEN1571, Balstilimab, AGEN2034, Botensilimab, AGEN1181
Agenus Inc.
Advanced Solid Tumor
12/24
12/24
Gabrielle, Anastasio
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patel, Manish
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
ANZUP 1301, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Active, not recruiting
3
501
Europe, RoW
Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia
Bladder Cancer
12/24
12/24
BTCRC-HN17-111, NCT03942653: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Recruiting
2
20
US
Goserelin Acetate, Pembrolizumab
Manish Patel, Merck Sharp & Dohme LLC
Salivary Gland Carcinoma
09/25
10/25
NCT04291105: Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
06/25
12/25
VitalBE, NCT03696290 / 2018-001590-24: Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Recruiting
2
77
Europe
Aztreonam lysine, Cayston, Placebo, Lactose monohydrate
University of Dundee, Gilead Sciences
Bronchiectasis Adult
09/25
09/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, ZIIHERA®, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
09/25
09/25
KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Recruiting
1/2
314
US
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Kineta Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
06/24
12/24
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
ARTS-021-1001, NCT05867251: Study of AVZO-021 in Patients With Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
AVZO-021, Palbociclib, Ibrance, Fulvestrant, Faslodex, Letrozole, Femara, Ribociclib, Kisqali, Abemaciclib, Verzenio, Carboplatin, Sacituzumab Govitecan-hziy, Trodelvy
Avenzo Therapeutics, Inc.
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
01/28
01/30
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25
NCT06065059: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Terminated
1/2
7
US
TNG348, Olaparib, Lynparza
Tango Therapeutics, Inc.
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
05/24
05/24
NCT06028074: Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Recruiting
1/2
111
US
GIM122, GIM-122
Georgiamune Inc
Advanced Solid Malignancies
09/26
12/26
REFMAL 412, NCT02617277: Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Active, not recruiting
1
56
US
AZD1775, Adavosertib, MEDI4736, Durvalumab
AstraZeneca
Advanced Solid Tumours
04/19
12/25
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
KEYNOTE-D26, NCT04840394: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Completed
1
1
US
BDB018, Pembrolizumab
Eikon Therapeutics, Merck Sharp & Dohme LLC
Tumor, Solid
03/24
09/24
IO-108-CL-001, NCT05054348: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Completed
1
91
US
IO-108, IO-108 + pembrolizumab combination therapy, IO-108 + Keytruda combination therapy, IO-108 + cemiplimab combination therapy, IO-108 + Libtayo combination therapy
Immune-Onc Therapeutics, Regeneron Pharmaceuticals
Solid Tumor, Adult
04/24
05/24
FT825-101, NCT06241456: FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, with or Without Monoclonal Antibodies in Advanced Solid Tumors

Recruiting
1
351
US
FT825, ONO-8250, Fludarabine, FLUDARA, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab
Fate Therapeutics
Advanced Solid Tumor
05/29
05/44
CUSP06-1001, NCT06234423: A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Recruiting
1
180
US
CUSP06
OnCusp Therapeutics, Inc.
Ovarian Cancer, Solid Tumor
05/27
08/27
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
07/25
10/25
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
CLN-418-001, NCT05306444: CLN-418 Study on Subjects With Advanced Solid Tumors

Completed
1
48
US, RoW
CLN-418, HBM7008
Harbour BioMed US, Inc., Harbour BioMed US, Inc.
Advanced Solid Tumor
08/24
09/24
NCT06714617: Phase 1 Open-Label Study BL-M17D1 w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Recruiting
1
120
US
BL-M17D1
SystImmune Inc.
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
09/27
12/27
CPO301-US-101, NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
102
Canada, US
CPO301, SYS6010
Conjupro Biotherapeutics, Inc.
Cancer, Cancer, Lung
06/25
12/25
NCT05462873: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Active, not recruiting
1
30
Europe, Japan, US, RoW
QEQ278
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
09/25
09/25
NCT05377528: Study of AGEN1571 in Participants With Advanced Solid Tumors

Completed
1
22
US
AGEN1571, Balstilimab, AGEN2034, Botensilimab, AGEN1181
Agenus Inc.
Advanced Solid Tumor
12/24
12/24
Gabrielle, Anastasio
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29

Download Options